1Jemal A, Siegel R, Ward E, et al. Cancer statistics,2007. CA Cancer J Clin ,2007,57:43 - 66.
2Jean-Louis Pujol,Jean Grenier,et al. Serum Fragment of Cytokeratin Subunit 19 Measured by CYFRA 21-1 Immunoradiometric Assay as a Marker of Lung Cancer. CANCER RESEARCH 53. 61 -66. January 1. 1993.
3Joachim Schneider, Monika Philipp, et al. ProGRP, NSE, CEA and CYFRA21-1 in Patients with Lung Cancer in Comparison to other Lung Disease. Anticancer Research,2003, (23) :885 - 894.
6Schneider J, Velcovsky H G, Morr H, et al. Comparison of the tumormarkers tumor M2-PK,CEA,CYFRA 21-1 ,NSE and SCC in the diagnosis of lung cancer. Anticancer Res, 2000,20 ( 6D ) : 5053 - 5058.
7HisashiSuzuki, Shigemilshikawa, Hiroichilshikawa, HiroakiSatoh, TatsuoYamamoto, MasatakaOnizuka, YuzuruSakakibara, MitsuakiSakai. Preoperative CYFRA21-1 levels as a prognostic factor in c-stage Ⅰ non-small cell lung cancer. European Journal of Cardio-thoracic Surgery,32 ( 2007 ) :648 - 652.
8Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra21-1, neuron speciticenolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer,2001,31:221 -31.
9Katsunari Matsuoka, Shinichi Sumitomo, et al. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage Ⅰ non-small cell lung cancer. European Journal of Cardio-thoracic Surgery,32 ( 2007 ) :435 - 439.
10Fabrice Barlesi, Celine Gimenez, Jean-Philippe Torte, et al. Prognostic value of combination of Cyfra21-1, CEA and NSE in patients with advanced nonsmall cell lungcancer. Respiratory Medicine,2004, 98:357 - 362.
1Muley T, Ebert W, Stieber P, et al. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay [J]. Clin Chem Lab Med, 2003, 41(1) :95-103.
2Wu G P, Ba J, ZhaoY J, et al. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer [J]. Acta Cyto, 2007,51 (4) : 679-680.
3Hur J, Lee H J, Nam J E, et al. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer[ J]. BMC Cancer, 2012, 12:392.
4Ke P Y, Chang Z F. Mitotic degradation of human thymidine ki- nase 1 is dependent on the anaphase-promoting complex/cyclo- some-edhl-mediated pathway [ J ]. Mol Cell Biol, 2004,24 ( 2 ) : 514 -26.
5He E, Xu X H, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non- Hodgkin' s lymphoma [ J ]. Nucleosides Nucleotides Nucleic Acids,2010,29 (4-6) : 352 -8.
6Li X, Asmitananda T, Gao L, et al. Biomarkers in the lung canc- er diagnosis: a clinical perspective [ J]. Neoplasma, 2012, 59 (5) :500 -7.
7Xu Y,Shi Q L,Ma H,et al. High thymidine kinase 1 (TK1) ex- pression is a predictor of poor survival in patients with pTl of lmag adenocarcinoma[ J ]. Tumour Bio1,2012,33 (2) :475 - 83.
8Lee S, Lee C Y, Kim D J, et al. Pathologic correlation of serum carcinoembryanic antigen and cytokeratin 19 fragment in resected nonsmall cell lung cancer[ J]. Korean J Thorac Cardiovasc Surg, 2013,46(3) :192 -6.
9Holdenrieder S, yon Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first lineche- motherapy of small cell lung cancer[ J]. Clin Cancer Res,2008, 14(23) : 7813 -21.
10Satoh H, Ishikawa H, Kurishima K, et al. Cut-off levels of NSE to differentiate SCLC from NSCLC[ J]. OncolRep,2012,9(3):581 -583.
